Literature DB >> 28740590

Updates on the Management of Severe Asthma.

Atif Siddiqui1, Lisa Kopas1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28740590      PMCID: PMC5512687          DOI: 10.14797/mdcj-13-2-82

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


× No keyword cloud information.
  21 in total

1.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

Authors:  H Milgrom; R B Fick; J Q Su; J D Reimann; R K Bush; M L Watrous; W J Metzger
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

2.  Airway smooth muscle as a target for asthma therapy.

Authors:  Julian Solway; Charles G Irvin
Journal:  N Engl J Med       Date:  2007-03-29       Impact factor: 91.245

3.  Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.

Authors:  Leif Bjermer; Catherine Lemiere; Jorge Maspero; Sivan Weiss; James Zangrilli; Matthew Germinaro
Journal:  Chest       Date:  2016-04-04       Impact factor: 9.410

4.  Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma.

Authors:  Mario Castro; Adalberto Rubin; Michel Laviolette; Nicola A Hanania; Brian Armstrong; Gerard Cox
Journal:  Ann Allergy Asthma Immunol       Date:  2011-04-14       Impact factor: 6.347

Review 5.  The discovery and development of omalizumab for the treatment of asthma.

Authors:  Amelia Licari; GianLuigi Marseglia; Riccardo Castagnoli; Alessia Marseglia; Giorgio Ciprandi
Journal:  Expert Opin Drug Discov       Date:  2015-05-15       Impact factor: 6.098

6.  Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial.

Authors:  Mario Castro; Adalberto S Rubin; Michel Laviolette; Jussara Fiterman; Marina De Andrade Lima; Pallav L Shah; Elie Fiss; Ronald Olivenstein; Neil C Thomson; Robert M Niven; Ian D Pavord; Michael Simoff; David R Duhamel; Charlene McEvoy; Richard Barbers; Nicolaas H T Ten Hacken; Michael E Wechsler; Mark Holmes; Martin J Phillips; Serpil Erzurum; William Lunn; Elliot Israel; Nizar Jarjour; Monica Kraft; Narinder S Shargill; John Quiring; Scott M Berry; Gerard Cox
Journal:  Am J Respir Crit Care Med       Date:  2009-10-08       Impact factor: 21.405

7.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.

Authors:  Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague
Journal:  Eur Respir J       Date:  2013-12-12       Impact factor: 16.671

8.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

9.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

10.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.